ACR Image Metrix has formalized a biomarker and imaging development program.
ACR Image Metrix has partnered with radiopharmacies to overcome the challenging logistics of using radiolabeled tracers as biomarkers in clinical research and has formalized a biomarker imaging development program that includes clinical strategy, trial design and execution.
“ACR Image Metrix has experience and understands the challenges with biomarkers,” stated Michael J. Morales, General Manager. “Our operational expertise and infrastructure ensure our clients’ data meet regulatory requirements. Additionally, we are currently assisting several sponsors with their biomarker clinical development programs in multiple therapeutic categories. This is a new area for sponsors as well as the FDA, and ACR Image Metrix aims to add value to this new frontier in drug development.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.